1
|
He L, Takahashi K, Pasic L, Narui C, Ellinger P, Grundmann M, Takahashi T. The effects of CD148 Q276P/R326Q polymorphisms in A431D epidermoid cancer cell proliferation and epidermal growth factor receptor signaling. Cancer Rep (Hoboken) 2021; 5:e1566. [PMID: 34791835 PMCID: PMC9458507 DOI: 10.1002/cnr2.1566] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 08/16/2021] [Accepted: 09/21/2021] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND CD148 is a transmembrane protein tyrosine phosphatase that is expressed in multiple cell types. Previous studies have shown that CD148 dephosphorylates growth factor receptors and their signaling molecules, including EGFR and ERK1/2, and negatively regulates cancer cell growth. Furthermore, research of clinical patients has shown that highly linked CD148 gene polymorphisms, Gln276Pro (Q276P) and Arg326Gln (R326Q), are associated with an increased risk of several types of cancer. However, the biological effects of these missense mutations have not been studied. AIM We aimed to determine the biological effects of CD148 Q276P/R326Q mutations in cancer cell proliferation and growth factor signaling, with emphasis on EGFR signaling. METHODS CD148 forms, wild-type (WT) or Q276P/R326Q, were retrovirally introduced into A431D epidermoid carcinoma cells that lacks CD148 expression. The stable cells that express comparable levels of CD148 were sorted by flow cytometry. A431D cells infected with empty retrovirus was used as a control. CD148 localization, cell proliferation rate, EGFR signaling, and the response to thrombospondin-1 (TSP1), a CD148 ligand, were assessed by immunostaining, cell proliferation assay, enzyme-linked immunosorbent assay, and Western blotting. RESULTS Both CD148 forms (WT, Q276P/R326Q) were distributed to cell surface and all three cell lines expressed same level of EGFR. Compared to control cells, the A431D cells that express CD148 forms showed significantly lower cell proliferation rates. EGF-induced EGFR and ERK1/2 phosphorylation as well as cell proliferation were also significantly reduced in these cells. Furthermore, TSP1 inhibited cell proliferation in CD148 (WT, Q276P/R326Q)-expressing A431D cells, while it showed no effects in control cells. However, significant differences were not observed between CD148 WT and Q276P/R326Q cells. CONCLUSION Our data demonstrates that Q276P/R326Q mutations do not have major effects on TSP1-CD148 interaction as well as on CD148's cellular localization and activity to inhibit EGFR signaling and cell proliferation.
Collapse
Affiliation(s)
- Lilly He
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Keiko Takahashi
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Lejla Pasic
- Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, USA
| | - Chikage Narui
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - Philipp Ellinger
- Bayer AG Research & Development, Pharmaceuticals, Wuppertal, Germany
| | - Manuel Grundmann
- Bayer AG Research & Development, Pharmaceuticals, Wuppertal, Germany
| | - Takamune Takahashi
- Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee, USA
| |
Collapse
|
2
|
Wu Z, Hu Y, Chen S, Jia X, Deng F, Lai S. A novel polymorphism in the 3′ untranslated region of rabbit TAS1R1is associated with growth performance and carcass traits but not meat quality. CANADIAN JOURNAL OF ANIMAL SCIENCE 2019. [DOI: 10.1139/cjas-2018-0117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Zhoulin Wu
- Institute of Animal Genetics and Breeding, Sichuan Agricultural University, Chengdu Campus, Chengdu 611130, People’s Republic of China
| | - Yongsong Hu
- Chengdu Agricultural College, Chengdu 611130, People’s Republic of China
| | - Shiyi Chen
- Institute of Animal Genetics and Breeding, Sichuan Agricultural University, Chengdu Campus, Chengdu 611130, People’s Republic of China
| | - Xianbo Jia
- Institute of Animal Genetics and Breeding, Sichuan Agricultural University, Chengdu Campus, Chengdu 611130, People’s Republic of China
| | - Feilong Deng
- Institute of Animal Genetics and Breeding, Sichuan Agricultural University, Chengdu Campus, Chengdu 611130, People’s Republic of China
| | - Songjia Lai
- Institute of Animal Genetics and Breeding, Sichuan Agricultural University, Chengdu Campus, Chengdu 611130, People’s Republic of China
| |
Collapse
|
3
|
Iuliano R, Palmieri D, He H, Iervolino A, Borbone E, Pallante P, Cianflone A, Nagy R, Alder H, Calin GA, Trapasso F, Giordano C, Croce CM, de la Chapelle A, Fusco A. Role of PTPRJ genotype in papillary thyroid carcinoma risk. Endocr Relat Cancer 2010; 17:1001-6. [PMID: 20823296 PMCID: PMC3915780 DOI: 10.1677/erc-10-0143] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The strong genetic predisposition to papillary thyroid carcinoma (PTC) might be due to a combination of low-penetrance susceptibility variants. Thus, the research into gene variants involved in the increase of susceptibility to PTC is a relevant field of investigation. The gene coding for the receptor-type tyrosine phosphatase PTPRJ has been proposed as a cancer susceptibility gene, and its role as a tumor suppressor gene is well established in thyroid carcinogenesis. In this study, we want to ascertain the role of PTPRJ genotype in the risk for PTC. We performed a case-control study in which we determined the PTPRJ genotype for the non-synonymous Gln276Pro and Asp872Glu polymorphisms by PCR amplification and sequencing. We calculated allele and genotype frequencies for the considered polymorphisms of PTPRJ in a total sample of 299 cases (PTC patients) and 339 controls (healthy subjects) selected from Caucasian populations. We observed a significantly higher frequency of homozygotes for the Asp872 allele in the group of PTC patients than in the control group (odds ratio=1.61, 95% confidence interval 1.15-2.25, P=0.0053). We observed a non-significant increased frequency of homozygotes for Gln276Pro polymorphism in PTC cases in two distinct Caucasian populations. Therefore, the results reported here show that the homozygous genotype for Asp872 of PTPRJ is associated with an increased risk to develop PTC.
Collapse
Affiliation(s)
- Rodolfo Iuliano
- Dipartimento di Medicina Sperimentale e Clinica, Facoltà di Medicina e Chirurgia, Università degli Studi “Magna Græcia” di Catanzaro, viale Europa, 88100 Catanzaro, Italy
- Corresponding Authors Rodolfo Iuliano, Dipartimento di Medicina Sperimentale e Clinica, Facoltà di Medicina e Chirurgia, Università di Catanzaro, Campus “Salvatore Venuta” Viale Europa, località Germaneto, 88100 Catanzaro, Italy. Tel. +39-0961-3695182 Fax: +39-0961-3694090 Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II”,80131 Napoli, Italy. Tel. +39-081-3737857 Fax: +39-081-3737808
| | - Dario Palmieri
- Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II”,80131 Napoli, Italy
- NOGEC (Naples Oncogenomic Center) – CEINGE, Biotecnologie Avanzate, via Comunale Margherita, 482, 80145 Napoli, Italy
| | - Huiling He
- Division of Human Cancer Genetics, Comprehensive Cancer Center, Ohio State University, 460 West 12th Avenue, Columbus, Ohio, 43210, USA
| | - Angela Iervolino
- Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II”,80131 Napoli, Italy
- NOGEC (Naples Oncogenomic Center) – CEINGE, Biotecnologie Avanzate, via Comunale Margherita, 482, 80145 Napoli, Italy
| | - Eleonora Borbone
- Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II”,80131 Napoli, Italy
- NOGEC (Naples Oncogenomic Center) – CEINGE, Biotecnologie Avanzate, via Comunale Margherita, 482, 80145 Napoli, Italy
| | - Pierlorenzo Pallante
- Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II”,80131 Napoli, Italy
- NOGEC (Naples Oncogenomic Center) – CEINGE, Biotecnologie Avanzate, via Comunale Margherita, 482, 80145 Napoli, Italy
| | - Alessandra Cianflone
- Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II”,80131 Napoli, Italy
| | - Rebecca Nagy
- Division of Human Cancer Genetics, Comprehensive Cancer Center, Ohio State University, 460 West 12th Avenue, Columbus, Ohio, 43210, USA
| | - Hansjuerg Alder
- Division of Human Cancer Genetics, Comprehensive Cancer Center, Ohio State University, 460 West 12th Avenue, Columbus, Ohio, 43210, USA
| | - George A. Calin
- Division of Human Cancer Genetics, Comprehensive Cancer Center, Ohio State University, 460 West 12th Avenue, Columbus, Ohio, 43210, USA
| | - Francesco Trapasso
- Dipartimento di Medicina Sperimentale e Clinica, Facoltà di Medicina e Chirurgia, Università degli Studi “Magna Græcia” di Catanzaro, viale Europa, 88100 Catanzaro, Italy
| | - Carla Giordano
- Sezione di Endocrinologia, DOSAC (Dipartimento di Oncologia Sperimentale ed Applicazioni Cliniche), Università di Palermo, Piazza delle Cliniche 2, 90127, Palermo, Italy
| | - Carlo M. Croce
- Division of Human Cancer Genetics, Comprehensive Cancer Center, Ohio State University, 460 West 12th Avenue, Columbus, Ohio, 43210, USA
| | - Albert de la Chapelle
- Division of Human Cancer Genetics, Comprehensive Cancer Center, Ohio State University, 460 West 12th Avenue, Columbus, Ohio, 43210, USA
| | - Alfredo Fusco
- Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II”,80131 Napoli, Italy
- NOGEC (Naples Oncogenomic Center) – CEINGE, Biotecnologie Avanzate, via Comunale Margherita, 482, 80145 Napoli, Italy
- Corresponding Authors Rodolfo Iuliano, Dipartimento di Medicina Sperimentale e Clinica, Facoltà di Medicina e Chirurgia, Università di Catanzaro, Campus “Salvatore Venuta” Viale Europa, località Germaneto, 88100 Catanzaro, Italy. Tel. +39-0961-3695182 Fax: +39-0961-3694090 Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II”,80131 Napoli, Italy. Tel. +39-081-3737857 Fax: +39-081-3737808
| |
Collapse
|
4
|
Abstract
Hyperekplexia is a rare, but potentially fatal, neuromotor disorder characterized by exaggerated startle reflexes and hypertonia in response to sudden, unexpected auditory or tactile stimuli. This disorder is primarily caused by inherited mutations in the genes encoding the glycine receptor (GlyR) alpha1 subunit (GLRA1) and the presynaptic glycine transporter GlyT2 (SLC6A5). In this study, systematic DNA sequencing of GLRA1 in 88 new unrelated human hyperekplexia patients revealed 19 sequence variants in 30 index cases, of which 21 cases were inherited in recessive or compound heterozygote modes. This indicates that recessive hyperekplexia is far more prevalent than previous estimates. From the 19 GLRA1 sequence variants, we have investigated the functional effects of 11 novel and 2 recurrent mutations. The expression levels and functional properties of these hyperekplexia mutants were analyzed using a high-content imaging system and patch-clamp electrophysiology. When expressed in HEK293 cells, either as homomeric alpha1 or heteromeric alpha1beta GlyRs, subcellular localization defects were the major mechanism underlying recessive mutations. However, mutants without trafficking defects typically showed alterations in the glycine sensitivity suggestive of disrupted receptor function. This study also reports the first hyperekplexia mutation associated with a GlyR leak conductance, suggesting tonic channel opening as a new mechanism in neuronal ligand-gated ion channels.
Collapse
|
5
|
van Puijenbroek M, Dierssen JWF, Stanssens P, van Eijk R, Cleton-Jansen AM, van Wezel T, Morreau H. Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer. J Mol Diagn 2006; 7:623-30. [PMID: 16258161 PMCID: PMC1867548 DOI: 10.1016/s1525-1578(10)60596-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
As the number of identified single-nucleotide polymorphisms (SNPs) increases, high-throughput methods are required to characterize the informative loci in large patient series. We investigated the feasibility of MassEXTEND LOH analysis using Sequenom's MassArray RT software, a mass spectrometry method, as an alternative to determine loss of heterozygosity (LOH). For this purpose, we studied the c.827A>C SNP (1176A>C p.Gln276Pro) in protein tyrosine phosphatase receptor type-J (PTPRJ), which is frequently deleted in human cancers. In sporadic colorectal cancer (CRC), c.827A>C showed allele-specific LOH of the c.827A allele, which is important because LOH of PTPRJ may be an early event during sporadic CRC. To elucidate the impact of this low-penetrance gene on familial CRC, we studied c.827A>C in 222 familial CRC cases and 156 controls. In 6.2% of the A/C genotyped CRC samples, LOH of c.827A was observed with MassEXTEND LOH analysis and confirmed by conventional sequencing. Furthermore, a case with LOH of c.827A showed no LOH in 22 synchronously detected adenomas, including one with malignant transformation. The importance of the PTPRJ- c.827A>C SNP appears to be limited in familial CRC. We conclude that MassEXTEND LOH analysis (using Sequenom's MassARRAY RT software) is a sensitive, high-throughput, and cost-effective method to screen SNP loci for LOH in formalin-fixed paraffin-embedded tissue.
Collapse
Affiliation(s)
- Marjo van Puijenbroek
- Leiden University Medical Center, Department of Pathology, Building L1Q, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
7
|
Powell N, Jeremiah S, Morishita M, Dudley E, Bethel J, Bogdanova T, Tronko M, Thomas G. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 2005; 205:558-64. [PMID: 15714593 DOI: 10.1002/path.1736] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
In this study, the frequency of BRAF mutation was investigated in a series of 67 cases of papillary thyroid cancer (PTC) in patients from Ukraine. Thirty-two patients were aged 30 years or older at the time of diagnosis and 35 were under 16. Tumour was microdissected from paraffin wax-embedded sections, DNA extracted, and the presence of the BRAF T1796A mutation demonstrated by two different methods: PCR followed by restriction enzyme digestion or primer extension assay and detection using MALDI-TOF mass spectrometry. Eighteen (58%) of the adult cases, but only one of the 35 cases aged less than 16 harboured a BRAF T1796A mutation. There was complete agreement between the two methods used, suggesting that the MALDI-TOF assay is a robust alternative to conventional mutation analysis. RET rearrangement was also examined in the young cohort. The overall frequency of RET rearrangement was 45.7%. Eight of the younger group of patients were born after 1 December 1986 and were therefore not exposed to radioiodine in fallout from Chernobyl. None of the PTCs from these eight patients were positive for BRAF mutation. The frequency of RET rearrangement was 44% in the 27 cases exposed to radiation and 50% in the eight not exposed. These results suggest that the different molecular biological profiles observed are associated with the age of the patient at diagnosis with PTC, rather than being associated with radiation exposure.
Collapse
Affiliation(s)
- Ned Powell
- Human Cancer Studies Group, The Clinical School, Swansea University, Singleton Park, Swansea, Wales, UK
| | | | | | | | | | | | | | | |
Collapse
|